Antibody-Mediated Rejection

Dear Colleagues,

The association between donor specific antibodies (HLA and non-HLA) and allograft dysfunction is well recognised. Antibody mediated rejection (AMR) in solid organ transplantation poses a significant threat to both short and long term graft survival. Although there have been significant recent advances in our understanding of pathogenesis, diagnosis, classification, and management, a great deal remains to be addressed.

The humoral response to an allograft is complex due to factors including: (1) specific characteristics of the donor specific antibodies, such as the timing of their development, quantity produced, affinity for antigens in vivo, and capacity to deposit in the allograft, fix complement and trigger inflammation; (2) interplay with the cellular allo-immune response; (3) dependence on innate immune responses for DSA production and effecting rejection; (4) control by conventional immunosuppressive agents; (5) interplay with novel modulators and mediators of immunity, including regulatory cells, innate lymphocytes and follicular cells. Determining why some, though not all, patients develop DSA, and why some DSAs cause rejection whilst others do not are key priorities in transplant research. A greater understanding of the processes involved in AMR will assist in developing the required multipronged management approach to prevent and treat this entity with the ultimate goal of improving graft survival.

This Special Issue of Antibodies focuses on the mechanisms that drive antibody-mediated immune responses in transplantation, as well the development of treatment regimes to improve allograft outcomes.

Prof. Dr. Steve Chadban
Associate Prof. Dr. Kate Wyburn
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• transplantation
• antibody mediated rejection
• HLA antibodies
• non-HLA antibodies
• sensitization
• donor-specific antibody (DSA)
• acute rejection
• graft survival
• humoral immune response